Investor Relations - SWK Holdings

Aimmune Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th

BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 2, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Jayson Dallas, M.D., will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2019, at 3:00 p.m. Pacific Time. Dr. Dallas will highlight recent progress, including the submission of a Biologics License Application to the U.S. Food and Drug Administration for AR101 in peanut allergy (ages 4-17), and provide an outlook for key milestones expected in 2019, including potential approval and launch of AR101 in the United States and planned filing for marketing approval in Europe. A Question and Answer session will immediately follow the presentation.

A live audio webcast of the presentation and Question and Answer session will be accessible from the Investor Relations section of the Aimmune Therapeutics website at www.aimmune.com. A replay of the webcast will be available at www.aimmune.com for at least 30 days following the webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for life-threatening food allergies. The company's Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA's Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age. Aimmune's regulatory filing for marketing approval of AR101 in the United States (submitted 4Q18) is based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials. Aimmune expects to file for marketing approval of AR101 in Europe in the first half of 2019. Aimmune has filed an IND application for its second product, AR201, for the treatment of egg allergy and intends to start a randomized Phase 2 clinical trial in the first half of 2019. For more information, please see www.aimmune.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune's expectations regarding the potential benefits of AR101; Aimmune's expectations regarding the potential commercial launch of AR101, including the timing of a potential approval of AR101; Aimmune's expectations regarding the planned timing and filing for marketing approval of AR101 in Europe; and Aimmune's expectations regarding potential applications of the CODIT™ approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the expectation that Aimmune will need additional funds to finance its operations; Aimmune's or any of its collaborative partners' ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmune's or any of its collaborative partners' clinical trials will not be successful; Aimmune's dependence on the success of AR101; Aimmune's reliance on third parties for the manufacture of Aimmune's product candidates; possible regulatory developments in the United States and foreign countries; and Aimmune's ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune's most recent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005161/en/

Source: Aimmune Therapeutics, Inc.

Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com

Media
Alison Marquiss, 650-376-5583
amarquiss@aimmune.com
